Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
September 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
August 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
August 26, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
August 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Leslie A. Brun Resigns from Merck Board of Directors
August 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
August 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2021 Financial Results
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2021 Dividend
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
VERQUVO® (vericiguat) Approved in the European Union
July 21, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
July 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
July 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
July 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
July 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
July 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
July 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
June 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
June 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Appoints Michael Klobuchar Chief Strategy Officer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
June 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Guggenheim Biopharma Strategy Series
June 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.